Clene shares are trading higher after the company announced improvement in vision and cognition with CNM-Au8 treatment in VISIONARY-MS trial long-term open label extension.
Portfolio Pulse from Benzinga Newsdesk
Clene Inc. reported positive results from the long-term open label extension of the VISIONARY-MS trial, with improvements in vision and cognition observed in patients treated with CNM-Au8. This news has led to an increase in Clene's stock price.
January 08, 2024 | 8:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene Inc. shares are experiencing an uptick following the announcement of successful trial results for its CNM-Au8 treatment, indicating potential improvements in vision and cognition for patients.
The positive outcome from the VISIONARY-MS trial is directly related to Clene's core product, CNM-Au8, and such results are likely to be viewed favorably by investors and could lead to increased investor confidence and a higher stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100